- Home
- REVB vs HSCS Comparison
REVB vs HSCS Comparison
Compare REVB & HSCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REVB
- HSCS
- Stock Information
- Founded
- REVB 2020
- HSCS 2007
- Country
- REVB United States
- HSCS United States
- Employees
- REVB N/A
- HSCS N/A
- Industry
- REVB Biotechnology: Pharmaceutical Preparations
- HSCS Medical Specialities
- Sector
- REVB Health Care
- HSCS Health Care
- Exchange
- REVB Nasdaq
- HSCS Nasdaq
- Market Cap
- REVB 3.8M
- HSCS 3.7M
- IPO Year
- REVB N/A
- HSCS 2022
- Fundamental
- Price
- REVB $2.88
- HSCS $3.94
- Analyst Decision
- REVB
- HSCS Strong Buy
- Analyst Count
- REVB 0
- HSCS 2
- Target Price
- REVB N/A
- HSCS $13.00
- AVG Volume (30 Days)
- REVB 269.2K
- HSCS 187.6K
- Earning Date
- REVB 08-08-2025
- HSCS 07-24-2025
- Dividend Yield
- REVB N/A
- HSCS N/A
- EPS Growth
- REVB N/A
- HSCS N/A
- EPS
- REVB N/A
- HSCS N/A
- Revenue
- REVB N/A
- HSCS $4,350.00
- Revenue This Year
- REVB N/A
- HSCS $21,003.45
- Revenue Next Year
- REVB N/A
- HSCS $533.33
- P/E Ratio
- REVB N/A
- HSCS N/A
- Revenue Growth
- REVB N/A
- HSCS N/A
- 52 Week Low
- REVB $2.11
- HSCS $2.36
- 52 Week High
- REVB $168.00
- HSCS $6.47
- Technical
- Relative Strength Index (RSI)
- REVB 44.79
- HSCS 49.70
- Support Level
- REVB $2.97
- HSCS $3.62
- Resistance Level
- REVB $3.18
- HSCS $4.14
- Average True Range (ATR)
- REVB 0.23
- HSCS 0.67
- MACD
- REVB 0.13
- HSCS -0.05
- Stochastic Oscillator
- REVB 60.37
- HSCS 12.15
About REVB Revelation Biosciences Inc.
Revelation Biosciences Inc is a clinical-stage life science company that is focused on rebalancing inflammation to optimize health using its proprietary formulation Gemini. It is developing a pipeline of potential high-value products based on Gemini. Gemini is Revelation's proprietary formulation of phosphorylated hexaacyl disaccharide (PHAD) an established TLR4 agonist that can stimulate the human body's innate immune response to prevent and treat disease. The product candidates are developed are based on Gemini formulation of PHAD. Gemini-based programs consist of: Gemini-SSI developed for the prevention of surgical site infection (SSI); Gemini-AKI developed for the prevention of acute kidney injury (AKI); and Gemini-CKD for the treatment of chronic kidney disease (CKD).
About HSCS Heart Test Laboratories Inc.
HeartSciences Inc is an artificial intelligence (AI)-powered medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease. Its objective is to improve healthcare by making it a far more valuable cardiac screening tool, particularly in frontline or point-of-care clinical settings. It is developing a suite of AI-ECG diagnostic solutions for use in any healthcare care setting, either via MyoVista Insights cloud-platform using one of the millions of ECG devices currently in clinical use or via MyoVista wavECG Device.